Latest PolyPid News & Updates

See the latest news and media coverage for PolyPid. We track all announcements, press releases, and industry mentions in real time, all in one place.

PolyPid

Developer of long-acting controlled-release medicines

polypid.com

Headquarters: Petah Tikva, Israel
Company type: Public company
Number of employees: 50–83
Industry: Pharmaceuticals

Last updated October 26

Latest news about PolyPid

In short: PolyPid presented D-PLEX100 data and advanced FDA and EMA reviews toward November 2026 decisions.

Company announcements

October 26 PolyPid

PolyPid unveils expanded pipeline strategy

The company introduces PD01B, a new kynatrix-based product candidate for diabetic foot infections, and hosts a virtual investor day event.

October 15 PolyPid

PolyPid hosts virtual investor day

Management outlines vision, updates on D-PLEX₁₀₀ and PD01B pipeline. Warren Joseph leads Q&A session.

October 1 PolyPid

PolyPid announces EMA validation and regained EU rights for D-PLEX100

The European Medicines Agency validated the Marketing Authorization Application, starting formal review. PolyPid also regained exclusive European commercialization rights from ADVANZ PHARMA.

August 12 PolyPid

PolyPid reports Q2 2026 financial results and corporate update

FDA accepted D-PLEX100 NDA with Priority Review; Azurity partnership brings $30M upfront, with PDUFA date November 28, 2026.

Media coverage

October 8 Markets Insider

What PolyPid's Bold Moves in Europe Could Mean for D-PLEX₁₀₀'s Global Potential (NASDAQ: PYPD)

WSW, NY, October 9th, 2026, FinanceWireTwo announcements on the same day put a validated European application and full...

October 1 The Globe and Mail

PolyPid Reclaims European Rights to D-PLEX₁₀₀ After Ending Advanz Pharma Deal

An announcement from PolyPid ( (PYPD)) is now available. On October 1, 2026, PolyPid announced it has regained exclusive European commercialization rights to its lead...

October 1 The Globe and Mail

PolyPid’s D-PLEX₁₀₀ Application Validated by EMA, Advancing Dual EU–U.S. Reviews

PolyPid announced on October 1, 2026 that the European Medicines Agency has validated its Marketing Authorization Application for D-PLEX₁₀₀, clearing the submission to enter formal...

September 29 Investing.com

PolyPid and Lytham Partners: FDA will soon decide on its lead drug

Legal notice: Trading in financial instruments or cryptocurrencies involves a high risk, including the partial or total loss of invested capital, and may not...

Never miss news about PolyPid

Track PolyPid and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

PolyPid competitors & trending companies

Browse news for competitors to PolyPid and other trending companies.